described a case of hemolytic anemia secondary to pembrolizumab in a NSCLC patient who, prior to ICI initiation, had severe anemia, a positive DAT (C3+, IgG–), and a cold agglutinin titer of 64, but no markers of hemolysis (44). This evidence concerns the gene C3 and anemia.